Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies.

Patients with lymphoproliferative diseases are at an increased risk of an incomplete immune response following vaccination or SARS‐CoV‐2 infection and might develop persistent viral infection and severe COVID‐19 disease. We present a case of successful treatment of persistent and mechanical‐ventilation‐requiring SARS‐CoV‐2 infection in a del17+ CLL patient using exogenous antibodies. Patients with chronic lymphocytic leukemia (CLL) might have an incomplete immune response following vaccination or SARS‐CoV‐2 infection. There is therapeutic potential of monoclonal antibodies in persistent and severe COVID‐19, mirrored in a CLL patient. [ABSTRACT FROM AUTHOR]